A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer
Lloyd Jones M, Hummel S, Bansback N, Orr B, Seymour M
Record ID 32002000314
English
Authors' objectives:
The objectives of this review are: 1. to evaluate the relative clinical effectiveness of irinotecan, oxaliplatin and raltitrexed in terms of disease progression rates 2. to estimate their relative effect on overall survival and quality-of-life-adjusted survival 3. to evaluate their side-effect profiles 4. to estimate the incremental cost-effectiveness of the three drugs in comparison with conventional therapy 5. to estimate the overall cost associated with the use of these drugs in England and Wales.
Authors' recommendations:
When used as first-line therapy, the combination of either irinotecan or oxaliplatin with an infusional fluorouracil and folinic acid (FU/FA) regimen appears to extend median progression-free survival by 23 months compared with FU/FA alone, although with increased toxicity; irinotecan has also been shown to extend overall survival. However, raltitrexed appears to reduce both progression-free and overall survival compared with FU/FA. When used as second-line treatment, irinotecan monotherapy appears to extend median progression-free survival by approximately 1 month and overall survival by approximately 2 months compared with FU/FA alone, again at the cost of increased toxicity. Preliminary data suggest that, as second-line treatment, oxaliplatin plus 5FU may extend median progression-free survival compared with either 5FU or irinotecan monotherapy.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1198
Year Published:
2001
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Costs and Cost Analysis
- Colorectal Neoplasms
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.